Mater Misericordiae
Mater Misericordiae
South Brisbane, Queensland, Australia3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-06-01 | NCT03900429 | |
| Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications, Infant, Newborn, Diseases, Infant, Premature, Diseases, Lung Injury, Obstetric Labor Complications, Obstetric Labor, Premature, Premature Birth, Thoracic Injuries, Urogenital Diseases, Ventilator-Induced Lung Injury, bronchopulmonary dysplasia, injury, lung disorder, pregnancy disorder, respiratory system disorder | Active, not recruiting | Not applicable | 2026-02-19 | NCT04372953 | |
| Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Death, Female Urogenital Diseases and Pregnancy Complications, Fetal Death, Fetal Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, fetal growth restriction, hereditary endocrine growth disease, pregnancy disorder, pregnancy disorder with abortive outcome | Recruiting | Phase 3 | 2025-06-06 | NCT05651347 |